JPRN-UMIN000019893已完成2 期
Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer - Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer
The Cancer Institute Hospital, Japanese Foundation for Cancer Research0 个研究点目标入组 35 人开始时间: 2015年11月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Receive blood infusion, G-CSF within 7days before primary registration. UGT1A1*28 homo, *6 homo,*28*6 Severe heart disease. Severe liver disease. Severe lung disease. Active gastrointestinal bleeding. Severe mental disease. Severe diabetes. Ileus. Active infectious disease. Other active cancer. Cerebral metastasis. Icterus . Severe diarrhea. Severe allergic reaction for drugs (irinotecan anti-EGFR antibody). Massive ascites, plerural effusion. Under treatment with atazanavir. Past history of treatment with EGFR antibody. Alcoholic or drug Intoxication. Hbs antibody positive. HCV antibody positive. HIV antibody positive. A pregnant woman, a woman in breast-feeding, a man who expects his baby. An inappropriate case judged by docter in charge.
研究者
相似试验
招募中
2 期
Phase II study of biweekly cetuximab and irinotecan for unresectable advanced/recurrent colorectal cancer. Phoenix studycolorectal cancerJPRN-UMIN000003483Kitasato University East Hospital Department of gastroenterological surgery, Department of gastroenterology38
已完成
2 期
Phase II study of biweekly cetuximab plus irinotecan for unresectable colorectal cancerJPRN-UMIN000001951Aichi Cancer Center Hospital30
已完成
2 期
Phase II study of biweekly cetuximab+irinotecan therapy for unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000011362Osaka City University20
进行中（未招募）
不适用
Phase II study of therapy with Cetuximab and Irinotecan every second week to Irinotecan resistant patients with metastatic colorectal cancer-effect and biological markersIn Denmark there is approximately 3600 new cases of Colorectal cancer every year. In Denmark about half of these patients will eventually develop metastatic disease. In Denmark it is suggested that 150 patients each year will be in such good performance to third line chemotherapy.MedDRA version: 9Level: 1.0Classification code 10010029EUCTR2006-001961-40-DKDepartment of Oncology, University Hospital Herlev100
招募中
2 期
Phase II trial of irinotecan with biweekly cetuximab in unresectable advanced and/or metastatic colorectal cancer, evaluation of the safety and efficacy based on EGFR positive and KRAS wild type.(i-BEX trial)advanced/metastatic colorectal cancerJPRN-UMIN000002761PO FMPC (Future Medicine Promoting Consortium)45